Laurus Labs Ltd
Laurus Labs Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
4 of 5 strong
The short version
Laurus Labs expects to maintain the current run rate in sales with a variation of plus/minus INR100 crores. Laurus Labs expects significant growth driven by its CDMO business, aiming for CDMO to contribute over 50% of revenues by FY 2030.
From Laurus Labs Ltd's Q1 FY27 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- Laurus Labs expects to maintain the current run rate in sales with a variation of plus/minus INR100 crores.
- Commercial sales within custom synthesis accounted for 50% in FY '26 and increased to 55% in 1Q FY '27, with expectations for growth in coming quarters and years.
- CDMO business shows strong growth potential, with confidence in significant growth driven by existing capacity and new capex.
- The company aims for CDMO revenue to contribute at least 50% of total turnover by FY '30.
- Laurus Bio's revenue contribution (currently 20% from animal origin-free ingredients and 60% from early-stage CDMO molecules) is expected to ramp up significantly over the next 18-24 months.
2 more points from Laurus Labs Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Laurus Labs Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capex guidance for FY '27 raised from INR1,500 crores to INR2,000 crores to meet customer demand and capacity expansion for multiple products and modalities (both small molecules and large peptides).
- Majority of the capex is targeted towards small molecule APIs and CDMO capacities.
- The company expects to invest significantly over FY '27 and FY '28, with indications that total capex for these two years may exceed INR3,000 crores.
- Investments are also ongoing in advanced biologics, including gene therapy, ADCs, and cell and gene therapy through technology licensing and partnerships (e.g., with Aarvik Therapeutics), which are expected to yield returns over 3-5 years.
2 more points from Laurus Labs Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Laurus Labs Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Laurus Labs does not disclose specific numbers on current or expected order book to avoid confusing investors, as program value varies greatly.
- The company handles a broad CDMO pipeline with both small and large-scale projects, with value of each program considered more important than the number of programs.
- CDMO business is well diversified with no single product or customer contributing significantly.
- The company has commercial programs and late-stage clinical projects, including approved products and those preparing for launch.
- Capital expenditure is closely aligned to specific customer needs and products requiring near-term capacity expansion.
2 more points from Laurus Labs Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Laurus Labs Ltd — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹1.8K Cr, net profit ₹282 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Laurus Labs Ltd's management said in earlier quarters
- Q3 FY25 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Trident Lifeline (Q1 FY27)
Q1 FY26: ₹23.6 crores . Key investor presentation takeaways from Trident Lifeline Ltd's Q1 FY27 investor presentation — and how it ranks against sector peers.
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjiv.Parant. (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
Arthneeti Pro · Annual
Laurus Labs Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Laurus Labs Ltd Q1 FY27 results?
Laurus Labs expects to maintain the current run rate in sales with a variation of plus/minus INR100 crores. Laurus Labs expects significant growth driven by its CDMO business, aiming for CDMO to contribute over 50% of revenues by FY 2030.
What is Laurus Labs Ltd share price analysis?
Laurus Labs Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 101.8 with a market cap of ₹111,337 Cr. Investors should review the full earnings analysis for detailed insights.
Is Laurus Labs Ltd planning capital expenditure?
Capex guidance for FY '27 raised from INR1,500 crores to INR2,000 crores to meet customer demand and capacity expansion for multiple products and modalities (both small molecules and large peptides).
Keep Laurus Labs Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.